title: Mitomycin C in photorefractive keratectomy: effect on epithelialization and predictability.
abstract: OBJECTIVE
  To evaluate the effect of topical mitomycin C (MMC) after myopic photorefractive keratectomy (PRK) on epithelialization and predictability.
  
  
  METHODS
  Prospective, randomized, double-masked, same-day, paired eye study.
  
  
  METHODS
  bilateral spherical equivalent (SE) between -6.5 and -10 D, difference of SE between the 2 eyes of < or =0.75 D, central pachymetry >520 microm, with a difference between the 2 eyes of <20 microm, follow-up 12 months. Planned optical zone was equal in the 2 eyes. After manual deepithelialization and excimer ablation, a Merocel sponge soaked either with MMC 0.2 mg/mL or with balanced salt solution was placed on the stromal bed of either eye for 45 seconds in a randomized fashion. A bandage contact lens was used until epithelialization; fluorometholone 0.1% eyedrops were symmetrically used and tapered in the 2 eyes.
  
  
  RESULTS
  Fifty-two patients (23 men; mean age, 33 years) completed the study. Preoperative mean SE was -8.07 +/- 0.92 D in the MMC eyes and -7.96 +/- 0.81 D in the control eyes (not statistically significant). Mean epithelialization time was 3.0 +/- 0.69 days in the MMC eyes and 3.0 +/- 0.71 days in the control eyes (not statistically significant). At 12 months, mean SE was 0.47 +/- 0.43 D in the MMC eyes and 0.17 +/- 0.49 D in the control eyes (P < 0.05). Mean haze in the MMC eyes was 0.02 +/- 0.07 and in the control eyes was 0.19 +/- 0.17 (P < 0.05).
  
  
  CONCLUSIONS
  MMC did not delay epithelialization and did not induce adverse effects at 12 months. MMC induced a mean 0.47-D overcorrection (5.8% of attempted correction). All eyes treated with MMC had a haze grade < or =0.25.
authors: Ophthalmic Surgery Unit, Casa di Cura Rugani, Siena, Italy. leccisotti@libero.it
authors: Antonio
authors: A
authors: Leccisotti
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000477:Alkylating Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D019573:Epithelium, Corneal / Q000502:physiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D054018:Lasers, Excimer; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects; D009216:Myopia / Q000188:drug therapy* / Q000601:surgery*; D018903:Photorefractive Keratectomy / Q000379:methods*; D011446:Prospective Studies; D014792:Visual Acuity / Q000502:physiology; D014945:Wound Healing / Q000502:physiology
chemical_list: D000477:Alkylating Agents; D016685:Mitomycin